Immunohistochemical assays incorporating SP142 and 22C3 monoclonal antibodies for detection of PD-L1 expression in NSCLC patients with known status of EGFR and ALK genes

Different immunohistochemical (IHC) assays were approved for PD-L1 expression examination on tumor cells in qualification to immune-checkpoint inhibitors therapy in NSCLC patients. These assays have some similarities, but also very serious differences. We assessed 2 IHC tests for PD-L1 expression ev...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Krawczyk, Paweł, Jarosz, Bożena, Kucharczyk, Tomasz, Grenda, Anna, Reszka, Katarzyna, Pankowski, Juliusz, Wojas-Krawczyk, Kamila, Nicoś, Marcin, Szumiło, Justyna, Trojanowski, Tomasz, Milanowski, Janusz
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5610002/
https://ncbi.nlm.nih.gov/pubmed/28969070
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.19724
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires